Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Heisen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Medical Research and Opinion|January 21, 2016
Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experimentsM Heisen, S A Baeten, B G Verheggen, et al.
Physics in Medicine and Biology|August 4, 2010
The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI dataM Heisen, X Fan, J Buurman, et al.
Journal of Medical Economics|June 29, 2012
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The NetherlandsM Heisen, M J Treur, W S van der Hel, et al.
Journal of Medical Economics|June 19, 2018
Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the NetherlandsM A Piena, M Heisen, L W Wormhoudt, et al.
Expert Review of Vaccines|January 18, 2021
Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United KingdomD A R Mathijssen, M Heisen, J F Clark-Wright, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Medical Research and Opinion|January 21, 2016
Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experimentsM Heisen, S A Baeten, B G Verheggen, et al.
Physics in Medicine and Biology|August 4, 2010
The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI dataM Heisen, X Fan, J Buurman, et al.
Journal of Medical Economics|June 29, 2012
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The NetherlandsM Heisen, M J Treur, W S van der Hel, et al.
Journal of Medical Economics|June 19, 2018
Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the NetherlandsM A Piena, M Heisen, L W Wormhoudt, et al.
Expert Review of Vaccines|January 18, 2021
Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United KingdomD A R Mathijssen, M Heisen, J F Clark-Wright, et al.
Pageof 1